Drug recall · August 24, 2022
PF-Labetalol HCl Injection recall
Why: CGMP Deviations: Potential for cross-contamination due to product carryover during manufacturing.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
PF-Labetalol HCl Injection, USP, 20 mg/4 mL (5 mg/mL), One 4 mL Unit-Dose Vial, packaged in 30 x 4 mL Sterile Unit-dose Vials per carton, Rx Only, Nephron 503B Outsourcing Facility, 4500 12th Street Extension, West Columbia, SC 29172; NDC 69374-946-34
- Lots / codes
Lot: LB2005A, Exp 3/2/2023
- Quantity
- 33,870 vials
- Company
- Nephron Sterile Compounding Center LLC, West Columbia, SC
- Distribution
- Nationwide in the USA
- Initiated
- August 10, 2022 · Voluntary: Firm initiated
- Classified
- August 16, 2022
- Reported
- August 24, 2022
- Ended
- October 11, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Labetalol
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.